drugset / Trial / NCT01747083

Food-Effect Bioavailability Study of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets)

NCT01747083

Phase 1 Completed 24 enrolled LG Life Sciences
RandomizedCrossoverOpen-label

Summary

This study is designed to investigate the food-effects on FDC(gemigliptin/metformin HCl sustained release) 50/1000mg(25/500mg x 2tablets)

Timeline

Start
2013-01
Primary completion
2013-03
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemigliptin Small molecule 50 mg
Subject Metformin Small molecule 1000 mg